ArticleACS omega2020
Physicochemical and Pharmacokinetic Analysis of Anacardic Acid Derivatives.
Article in ACS omega, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 85 citations in OpenAlex.
- AI-Driven Design and Comparative Evaluation of SNEDDS for the Optimized Nanoencapsulation of Phytoextracts.Nanomaterials (Basel, Switzerland) · 2026Article
- Synthesis, Structural Characterization, and In Silico Evaluation of the Salicylidene Schiff Base 4‑{(ACS omega · 2026Article
- Exploring the Potential of Anacardic Acid, its Natural and Synthetic Analogues, and Nanoformulations as a Potential Antibacterial Agent, including Multidrug-resistant Bacteria: A Comprehensive Review.Mini reviews in medicinal chemistry · 2026Review
- Synergistic Polyphenol Recovery FromJournal of analytical methods in chemistry · 2026Article
- Exploration of Canarium odontophyllum fruit phytoconstituents as potential candidates against epilepsy using in silico studies.Journal, genetic engineering & biotechnology · 2025Article
- Anacardic acid ameliorates insulin resistance and diabetic nephropathy: network pharmacology, in vivo and molecular docking studies targeting TNF- α / TGFβR1 signaling.Journal of natural medicines · 2025Article
- Article
- Structural Characterization and In Vitro and In Silico Studies on the Anti-Foods (Basel, Switzerland) · 2024Article
- Article
- A Comparative Analysis on the Potential Anticancer Properties of Tetrahydrocannabinol, Cannabidiol, and Tetrahydrocannabivarin Compounds Through In Silico Approach.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Exploring the potential of 2-arylbenzimidazole scaffolds as novel α-amylase inhibitors: QSAR, molecular docking, simulation and pharmacokinetic studies.In silico pharmacology · 2024Article
- Homology modeling, docking, and ADMET studies of benzoheterocyclic 4-aminoquinolines analogs as inhibitors ofJournal of Taibah University Medical Sciences · 2023Article
- Decreased HAT1 expression in granulosa cells disturbs oocyte meiosis during mouse ovarian aging.Reproductive biology and endocrinology : RB&E · 2023Article
- Absolute Stereochemistry and Cytotoxic Effects of Vismione E from Marine Sponge-Derived FungusInternational journal of molecular sciences · 2023Article
- Identifying potential ligand molecules EGFR mediated TNBC targeting the kinase domain-identification of customized drugs throughResearch in pharmaceutical sciences · 2023Article
- Potential antiviral activities of chrysin against hepatitis B virus.Gut pathogens · 2023Article
- Inhibition Kinetics and Theoretical Studies onJournal of xenobiotics · 2023Article
- Article
- Article
- In Silico Antiprotozoal Evaluation of 1,4-Naphthoquinone Derivatives against Chagas and Leishmaniasis Diseases Using QSAR, Molecular Docking, and ADME Approaches.Pharmaceuticals (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anacardic acid (AA) and its derivatives are well-known for their therapeutic applications ranging from antitumor, antibacterial, antioxidant, anticancer, and so forth. However, their poor pharmacokinetic and safety properties create significant hurdles in the formulation of the final drug molecule. As a part of our endeavor to enhance the potential and exploration of the anticancer activities, a detailed study on the properties of selected AA derivatives was performed in this work. A comprehensive analysis of the drug-like properties of 100 naturally occurring AA derivatives was performed, and the results were compared with certain marketed anticancer drugs. The work focused on the understanding of the interplay among eight physicochemical properties. The relationships between the physicochemical properties, absorption, distribution, metabolism, and excretion attributes, and the in silico toxicity profile for the set of AA derivatives were established. The ligand efficacy of the finally scrutinized 17 AA derivatives on the basis of pharmacokinetic properties and toxicity parameters was further subjected to dock against the potential anticancer target cyclin-dependent kinase 2 (PDB ID: 1W98). In the docked complex, the ligand molecules (AA derivatives) selectively bind with the target residues, and a high binding affinity of the ligand molecules was ensured by the full fitness score using the SwissDock Web server. The BOILED-Egg model shows that out of 17 scrutinized molecules, 3 molecules exhibit gastrointestinal absorption capability and 14 molecules exhibit permeability through the blood-brain barrier penetration. The analysis can also provide some useful insights to chemists to modify the existing natural scaffolds in designing new anacardic anticancer drugs. The increased probability of success may lead to the identification of drug-like candidates with favorable safety profiles after further clinical evaluation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.